Acadian Asset Management’s Royalty Pharma RPRX Stock Holding History

Acadian Asset Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.49M	Buy	44,401 +30,134	+211%	+$1.57M	﹤0.01%	1023
2026 Q1	$684K	Buy	+14,267	New	+$625K	﹤0.01%	1276
2025 Q3	–	Sell	-8,929	Closed	-$321K	–	1971
2025 Q2	$321K	Buy	+8,929	New	+$296K	﹤0.01%	1222
2025 Q1	–	Sell	-10,944	Closed	-$278K	–	1789
2024 Q4	$278K	Buy	+10,944	New	+$290K	﹤0.01%	1193
2024 Q3	–	Sell	-9,516	Closed	-$250K	–	2304
2024 Q2	$250K	Buy	+9,516	New	+$264K	﹤0.01%	1378
2024 Q1	–	Sell	-142,790	Closed	-$4.01M	–	1750
2023 Q4	$4.01M	Buy	142,790 +36,427	+34%	+$1M	0.02%	513
2023 Q3	$2.88M	Buy	106,363 +59,596	+127%	+$1.77M	0.01%	590
2023 Q2	$1.44M	Buy	46,767 +43,625	+1,388%	+$1.48M	0.01%	790
2023 Q1	$113K	Buy	+3,142	New	+$116K	﹤0.01%	1370
2022 Q3	–	Sell	-24,571	Closed	-$1.03M	–	1820
2022 Q2	$1.03M	Buy	+24,571	New	+$1.01M	0.01%	808
2021 Q1	–	Sell	-782	Closed	-$39K	–	2288
2020 Q4	$39K	Sell	782 -2,679	-77%	-$114K	﹤0.01%	1999
2020 Q3	$146K	Buy	+3,461	New	+$148K	﹤0.01%	1559

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Acadian Asset Management's RPRX Position: Q2 2026 in Review

Acadian Asset Management increased its Royalty Pharma (RPRX) stake by 211% in Q2 2026, buying an estimated $1.57M and bringing the position to 44,401 shares worth $2.49M. The position accounts for ﹤0.01% of the portfolio, ranked #1023.

Acadian Asset Management first reported a position in RPRX in Q3 2020 and has held it in 12 quarters since. The position peaked at $4.01M in Q4 2023. 647 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Acadian Asset Management held 44,401 shares of Royalty Pharma worth $2.49M as of Q2 2026.
Acadian Asset Management bought 30,134 Royalty Pharma shares in Q2 2026, an estimated $1.57M.
Royalty Pharma made up ﹤0.01% of Acadian Asset Management's portfolio in Q2 2026, its #1023 holding.
Acadian Asset Management first reported a position in Royalty Pharma in Q3 2020 and has held it in 12 quarters since.
Acadian Asset Management's Royalty Pharma position peaked at $4.01M in Q4 2023.
647 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.